ISCC reports positive preclinical results on its stem cell treatment for Criggler-Najjar syndrome

International Stem Cell Corporation (ISCC), a California based biomedical company, just announced via a press release positive preclinical results on their patented stem cell treatment for Criggler-Najjar syndrome type 1 (CN1). The study was conducted on a CN1 rodent model and it showed that the company's patented stem cell therapy is both efficient and safe. The press release fails to properly cite the study, so we redistribute the company's claims with caution.Full Story